AR078504A1 - Compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene - Google Patents
Compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contieneInfo
- Publication number
- AR078504A1 AR078504A1 ARP100103609A ARP100103609A AR078504A1 AR 078504 A1 AR078504 A1 AR 078504A1 AR P100103609 A ARP100103609 A AR P100103609A AR P100103609 A ARP100103609 A AR P100103609A AR 078504 A1 AR078504 A1 AR 078504A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- denotes
- integer
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical group 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 108010093894 Xanthine oxidase Proteins 0.000 abstract 1
- 102100033220 Xanthine oxidase Human genes 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a compuestos que son eficaces como un inhibidor para la xantina-oxidasa, a un proceso para preparar los mismos y a una composicion farmacéutica que comprende una cantidad terapéuticamente efectiva de los mismos. Reivindicacion 1: Compuestos de la siguiente formula (1): en la formula (1) anterior, A se selecciona entre los siguientes sustituyentes A-i, A-ii, A-iii, A-iv, A-v, A-vi, A-vii y A-viii: (A-i a A-iii) en la cual J representa hidrogeno, halogeno, o halogeno-alquilo C1-6 sustituido o insustituido, X representa O o S, Z representa C o N, E representa hidrogeno, halogeno, ciano, nitro, alquilo C1-6 sustituido o insustituido, o alcoxi C1-6 sustituido o insustituido, D representa hidrogeno, halogeno, ciano, nitro, halogeno-alquilo C1-6 sustituido o insustituido, -CHO, o -CH=N-OH, Q se selecciona entre los sustituyentes: hidrogeno; alquilo sustituido o insustituido, saturado o insaturado y de cadena recta, ramificada o cíclica; (2) (donde W representa O o S, R7 representa hidrogeno, o alquilo inferior sustituido o insustituido, y n denota un numero entero de 0 3); (3) (donde W representa O o S, R8 y R9, cada uno de ellos, representa hidrogeno o alquilo inferior, y m denota un numero entero de 1 3); (4) (donde R8 y R9, cada uno de ellos, representa hidrogeno o alquilo inferior, y m denota un numero entero de 1 3); (5) (donde R10 y R11, cada uno de ellos, representa hidrogeno, halogeno, alcoxi inferior o alquilo inferior, y m denota un numero entero de 1 3); (6) (donde R12 representa alquilo inferior sustituido o insustituido o un grupo aromático, y n denota un numero entero de 0 3); (7) (donde R13 y R14, cada uno de ellos, representa alquilo inferior sustituido o insustituido o, junto con el grupo N al cual están unidos, pueden formar un heterociclo de 3 a 7 miembros, y n denota un numero entero de 0 3); (8) (donde R15 representa alquilo inferior sustituido o insustituido, y m denota un numero entero de 1 3); (9) (donde m denota un numero entero de 1 3); (donde R15 representa alquilo inferior sustituido o insustituido, y m denota un numero entero de 1 3); Y representa hidrogeno, halogeno, alquilo sustituido o insustituido, saturado o insaturado y de cadena recta, ramificada o cíclica, alcoxi C1-6 sustituido o insustituido, o un grupo aromático o heteroaromático sustituido o insustituido, y G representa hidrogeno o representa alquilo sustituido o insustituido, saturado o insaturado y de cadena recta, ramificada o cíclica, sales farmacéuticamente aceptables o isomeros de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20090095363 | 2009-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078504A1 true AR078504A1 (es) | 2011-11-09 |
Family
ID=43857261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103609A AR078504A1 (es) | 2009-10-07 | 2010-10-05 | Compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8729273B2 (es) |
| EP (1) | EP2467378B1 (es) |
| JP (1) | JP5702392B2 (es) |
| KR (1) | KR101751325B1 (es) |
| CN (1) | CN102574839B (es) |
| AP (1) | AP3346A (es) |
| AR (1) | AR078504A1 (es) |
| AU (1) | AU2010304091B2 (es) |
| BR (1) | BR112012007828B8 (es) |
| CA (1) | CA2774133C (es) |
| CL (1) | CL2012000738A1 (es) |
| CO (1) | CO6430501A2 (es) |
| EA (1) | EA021025B1 (es) |
| EC (1) | ECSP12011793A (es) |
| ES (1) | ES2599829T3 (es) |
| IL (1) | IL218669A (es) |
| MA (1) | MA33880B1 (es) |
| MX (1) | MX2012003782A (es) |
| MY (1) | MY162813A (es) |
| PE (1) | PE20121088A1 (es) |
| SG (1) | SG179186A1 (es) |
| TR (1) | TR201203989T1 (es) |
| TW (1) | TWI423962B (es) |
| UA (1) | UA110197C2 (es) |
| WO (1) | WO2011043568A2 (es) |
| ZA (1) | ZA201202544B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI548630B (zh) * | 2011-04-06 | 2016-09-11 | Ｌｇ生命科學有限公司 | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法 |
| WO2013033085A1 (en) * | 2011-08-30 | 2013-03-07 | Stephen Martin Courtney | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| LT2980085T (lt) | 2013-03-29 | 2018-05-10 | Teijin Pharma Limited | Pirazolo darinys |
| US10258621B2 (en) | 2014-07-17 | 2019-04-16 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
| CN104774172B (zh) * | 2015-04-08 | 2017-03-22 | 河南师范大学 | 一种3‑氰基吲哚类化合物的合成方法 |
| CA2994336C (en) * | 2015-09-02 | 2024-03-05 | Sunshine Lake Pharma Co., Ltd. | Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof |
| CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
| EP3548066A1 (en) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| CN110612286A (zh) * | 2017-02-28 | 2019-12-24 | 广东东阳光药业有限公司 | 氰基取代的稠合双环衍生物及其制备方法和用途 |
| HRP20250709T1 (hr) | 2018-05-18 | 2025-08-15 | Bioverativ Therapeutics Inc. | Postupci liječenja hemofilije a |
| US11407744B2 (en) * | 2018-06-01 | 2022-08-09 | Autophagysciences Inc. | Compound and pharmaceutical composition comprising same |
| CN111072647B (zh) * | 2019-12-11 | 2021-02-26 | 沈阳药科大学 | 3-取代吲哚-5-氧代-4,5-二氢-1,2,4-噁二唑类化合物及其用途 |
| CN111072634B (zh) * | 2020-01-03 | 2022-07-22 | 中国医科大学 | 1-取代-3-取代-5-取代酰胺-1h-吲哚类化合物及其制备方法和应用 |
| TW202509020A (zh) | 2020-11-04 | 2025-03-01 | 南韓商Ｌｇ化學股份有限公司 | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶之製備方法及包含彼之醫藥組成物 |
| EP4257124A4 (en) | 2020-12-01 | 2024-05-29 | Lg Chem, Ltd. | ORAL FORMULATION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBOXYLIC ACID AND PREPARATION METHOD THEREFOR |
| EP4257123A4 (en) * | 2020-12-01 | 2024-05-08 | Lg Chem, Ltd. | STABLE ORAL FORMULATION CONTAINING 1-(3-CYANO-1-ISOPROPYL-5-YL)PYRAZOLE-4-CARBOXYLIC ACID |
| CN112920170B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | N-（吲哚-5-基）芳香杂环酰胺类化合物及其制备方法和用途 |
| US20240216331A1 (en) | 2021-04-16 | 2024-07-04 | Lg Chem, Ltd. | Oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid |
| KR102708081B1 (ko) * | 2021-04-27 | 2024-09-20 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
| WO2022231261A1 (ko) * | 2021-04-27 | 2022-11-03 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제 합성을 위한 중간체의 제조 방법 |
| KR20220147531A (ko) * | 2021-04-27 | 2022-11-03 | 주식회사 엘지화학 | 잔틴 옥시다아제 저해제의 제조 방법 |
| EP4335844A4 (en) * | 2021-05-07 | 2025-08-27 | Jiangsu Atom Bioscience And Pharmaceutical Co Ltd | CLASS OF XANTHINE OXIDASE INHIBITORS |
| JP2024520150A (ja) | 2021-06-15 | 2024-05-21 | エルジー・ケム・リミテッド | １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物 |
| AR126164A1 (es) * | 2021-06-17 | 2023-09-27 | Lg Chemical Ltd | Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
| TWI822151B (zh) | 2021-07-02 | 2023-11-11 | 南韓商Ｌｇ化學股份有限公司 | 製備黃嘌呤氧化酶抑制劑的方法 |
| AR126353A1 (es) | 2021-07-02 | 2023-10-11 | Lg Chemical Ltd | Método de preparación de productos intermedios para sintetizar un inhibidor de xantina oxidasa |
| JP7792730B2 (ja) * | 2022-04-27 | 2025-12-26 | 杭州新元素▲薬▼▲業▼有限公司 | 尿酸を降下させるために使用できる化合物 |
| TW202342455A (zh) * | 2022-04-27 | 2023-11-01 | 大陸商江蘇新元素醫藥科技有限公司 | 可用於痛風的化合物 |
| CN116283946B (zh) * | 2023-03-27 | 2024-05-07 | 武汉工程大学 | 5-(n-取代吲哚-5-基)异噁唑-3-甲酸衍生物及其合成方法和应用 |
| TW202509022A (zh) * | 2023-07-10 | 2025-03-01 | 南韓商Ｌｇ化學股份有限公司 | 製備用於合成黃嘌呤氧化酶抑制劑之中間體之方法 |
| CN118598859B (zh) * | 2024-05-21 | 2025-08-19 | 武汉工程大学 | 一种含氮杂环吲哚类黄嘌呤氧化酶抑制剂及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0513379T3 (da) | 1990-11-30 | 1996-09-30 | Teijin Ltd | 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne |
| ID21775A (id) | 1996-10-25 | 1999-07-22 | Yoshitomi Pharmaceutical | Senyawa-senyawa 1-fenilpirazol dan penggunaan farmasinya |
| CA2414468A1 (en) * | 2000-06-30 | 2002-01-10 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| ES2250422T3 (es) * | 2000-07-10 | 2006-04-16 | Bristol-Myers Squibb Company | Composicion y actividad antiviral de derivados de piperazina indoloxoaceticos sustituidos. |
| WO2008011131A2 (en) * | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
| DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
| AU2003249535A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
| JPWO2007004688A1 (ja) | 2005-07-01 | 2009-01-29 | 日本ケミファ株式会社 | キサンチンオキシダーゼ阻害剤 |
| JP5040656B2 (ja) | 2005-10-07 | 2012-10-03 | アステラス製薬株式会社 | トリアリールカルボン酸誘導体 |
| US8188113B2 (en) * | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| JP2008179621A (ja) * | 2006-12-28 | 2008-08-07 | Taisho Pharmaceutical Co Ltd | 含窒素飽和複素環化合物 |
| WO2008126770A1 (ja) | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体の製造方法 |
| EP2133331A4 (en) | 2007-04-11 | 2011-06-22 | Kissei Pharmaceutical | FIVE-GLASS HETEROCYCLIC DERIVATIVE AND ITS USE IN MEDICAL PURPOSES |
| PT2133332E (pt) | 2007-04-11 | 2013-10-03 | Kissei Pharmaceutical | Derivado de (aza)indole e sua utilização para fins médicos |
| EP2338887A4 (en) | 2008-10-15 | 2012-05-09 | Kissei Pharmaceutical | FUSIONED HETEROCYCLIC DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES |
| CA2912970C (en) | 2008-10-16 | 2017-04-18 | James M. Tuyls | Apparatus and method and turntable for on-demand distributing of a food product |
| WO2010045188A1 (en) * | 2008-10-17 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as mmp-13 inhibitors |
| CA2771026A1 (en) * | 2009-09-24 | 2011-03-31 | F. Hoffmann-La Roche Ag | Indole derivatives as crac modulators |
-
2010
- 2010-10-01 TW TW099133473A patent/TWI423962B/zh active
- 2010-10-04 WO PCT/KR2010/006760 patent/WO2011043568A2/en not_active Ceased
- 2010-10-04 SG SG2012018768A patent/SG179186A1/en unknown
- 2010-10-04 US US13/498,253 patent/US8729273B2/en active Active
- 2010-10-04 CA CA2774133A patent/CA2774133C/en active Active
- 2010-10-04 CN CN201080044868.1A patent/CN102574839B/zh active Active
- 2010-10-04 PE PE2012000438A patent/PE20121088A1/es active IP Right Grant
- 2010-10-04 EA EA201270520A patent/EA021025B1/ru unknown
- 2010-10-04 AP AP2012006191A patent/AP3346A/xx active
- 2010-10-04 BR BR112012007828A patent/BR112012007828B8/pt active IP Right Grant
- 2010-10-04 UA UAA201204342A patent/UA110197C2/ru unknown
- 2010-10-04 MA MA34731A patent/MA33880B1/fr unknown
- 2010-10-04 KR KR1020100096578A patent/KR101751325B1/ko active Active
- 2010-10-04 EP EP10822213.4A patent/EP2467378B1/en active Active
- 2010-10-04 ES ES10822213.4T patent/ES2599829T3/es active Active
- 2010-10-04 AU AU2010304091A patent/AU2010304091B2/en active Active
- 2010-10-04 TR TR2012/03989T patent/TR201203989T1/xx unknown
- 2010-10-04 JP JP2012533074A patent/JP5702392B2/ja active Active
- 2010-10-04 MX MX2012003782A patent/MX2012003782A/es active IP Right Grant
- 2010-10-04 MY MYPI2012700104A patent/MY162813A/en unknown
- 2010-10-05 AR ARP100103609A patent/AR078504A1/es active IP Right Grant
-
2012
- 2012-03-15 IL IL218669A patent/IL218669A/en active IP Right Grant
- 2012-03-23 CL CL2012000738A patent/CL2012000738A1/es unknown
- 2012-03-23 EC ECSP12011793 patent/ECSP12011793A/es unknown
- 2012-03-23 CO CO12049241A patent/CO6430501A2/es active IP Right Grant
- 2012-04-10 ZA ZA2012/02544A patent/ZA201202544B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078504A1 (es) | Compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene | |
| CO2020014217A2 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos | |
| CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
| UY33183A (es) | Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento | |
| UY33775A (es) | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos | |
| UY32793A (es) | Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| MX2019010736A (es) | Inhibidor del antigeno de superficie del virus de la hepatitis b. | |
| PE20161368A1 (es) | Inhibidores de diacilglicerol aciltranferasa 2 | |
| ECSP12012103A (es) | Inhibidores de virus flaviviridae. | |
| AR064561A1 (es) | Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina. | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| PE20171057A1 (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| PE20191744A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
| CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
| AR087182A1 (es) | DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| PE20210667A1 (es) | Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1 | |
| PA8815201A1 (es) | Compuestos heterociclicos | |
| AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
| PH12014501283A1 (en) | 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| CO7240410A2 (es) | Inhibidores macrocíclicos de virus flaviviridae | |
| AR094790A1 (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| BR112013004662B8 (pt) | Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |